NICE Guidelines + UK Prescribing for UKMLA: The IMG Gap

If you have trained outside the UK, the single biggest unforced error on the UKMLA AKT is answering a clinical scenario with pharmacology that is medically correct but not what a UK F1 would actually prescribe. The AKT is not a test of global best practice. It is a test of what a newly qualified UK doctor should do in a UK hospital or GP surgery on Monday morning — and that answer is defined by NICE, the BNF, and local formularies, not UpToDate or WHO algorithms.

This is the quietest UKMLA trap. UK medical students absorb NICE ladders by osmosis across five years of placements. IMGs arriving from the US, India, Nigeria, Egypt, or the EU often do not, because their clinical training used a different evidence framework. They walk into the AKT fluent in cardiology and come out below the pass mark on the prescribing stem because they picked amlodipine as step 1 for hypertension in a 45-year-old when NICE says the answer is an ACE inhibitor.

This guide is the systematic fix. We will cover how the UKMLA actually tests NICE knowledge, the 20 conditions whose guidelines you must know cold, the BNF features that save time on prescribing stems, the UK-vs-US drug-naming pitfalls that catch even experienced IMGs, and a practical extraction protocol for working through a NICE CKS page in 12 minutes flat. Written for the 2026 AKT cohort and aligned with the current GMC content map.

Table of contents

1. Why NICE matters for UKMLA
2. NICE CKS structure — how to navigate
3. Top 20 high-yield NICE conditions
4. NICE stepwise ladders explained
5. How UKMLA tests NICE knowledge
6. UK vs US prescribing differences
7. BNF structure and drug interactions
8. Drug naming pitfalls
9. Renal dosing essentials
10. Cost-efficacy reasoning (UK generic-first)
11. Extracting high-yield points from NICE pages
12. Exam technique: NICE-aligned answers
13. Free vs paid NICE resources
14. Q-bank practice for NICE-based questions
15. FAQ

1. Why NICE matters for UKMLA

The GMC content map that underpins the UKMLA explicitly references NICE guidance as the benchmark for UK clinical practice. Every AKT stem with a management or prescribing component is written against this benchmark. When the question asks "what is the most appropriate next step?" and offers you five plausible clinical options, "most appropriate" means most appropriate per NICE — not per your previous training, not per a US registrar, not per the most recent paper you read.

This matters more for prescribing stems than for any other question type. A purely diagnostic stem has a physiological right answer that is usually culturally neutral — a widened QRS with tall tented T waves is hyperkalaemia whether you trained in Manchester or Mumbai. But a stem that says "which antihypertensive would you start first?" in a 45-year-old of White British ethnicity has only one correct answer on AKT day (an ACE inhibitor) and three answers that would be perfectly reasonable in other healthcare systems (amlodipine, a thiazide, a beta-blocker). The AKT is asking: do you know UK practice?

Examiners know IMGs struggle here. They write stems specifically to discriminate between candidates who have internalised UK guidelines and those who have not. If you are an IMG and you work through the 12-week UKMLA plan without systematically mapping NICE-based decisions into your study, you will leak marks every prescribing question — typically 15–25% of a 200-question paper. That alone can be the difference between passing and scraping a fail.

The good news: NICE is finite. There are roughly 400 CKS topics, perhaps 50 of them are tested aggressively, and the core stepwise ladders for 20 conditions cover the vast majority of exam prescribing stems. This post teaches you which 20, how to extract them, and how to answer aligned to them under timed pressure.

2. NICE CKS structure — how to navigate

NICE publishes multiple layers of guidance. For UKMLA purposes only two matter: NICE Clinical Knowledge Summaries (CKS) and NICE Guidelines (NG). You can safely ignore Technology Appraisals (TAs), Quality Standards (QS), and Interventional Procedures (IPG) for the AKT.

CKS is the GP-facing summary format. Every CKS page has the same six-section structure:

1. Summary — a one-paragraph overview. Read this first.
2. Background information — epidemiology and aetiology. Skim; rarely examined verbatim.
3. Diagnosis — differential, history, examination, investigations. Moderate yield.
4. Management — the gold mine. This is where the stepwise ladder lives.
5. Prescribing information — dose ranges, cautions, monitoring. High yield.
6. References — skip.

The single most important tab for UKMLA revision is Management → Scenario → Step 1/2/3. Every CKS page breaks management down by clinical scenario (e.g. "Adult with newly diagnosed HTN, no comorbidity" vs "Adult with HTN and T2DM") and then lists the stepwise escalation for that scenario. Those stepwise ladders are what stems test.

NICE Guidelines (NG) are the longer, secondary-care-facing documents. They are the authoritative source but are too long to read cover to cover. Use them as a reference when a CKS page is unclear or when the condition is hospital-based (e.g. acute STEMI management lives in NG185, not CKS).

Navigation rule: if it's a GP-manageable condition, start with CKS. If it's an acute-care condition, go straight to the relevant NG. Either way, your goal on each page is to extract the stepwise ladder, the monitoring schedule, and any red-flag triggers for referral. Nothing else for exam purposes.

3. Top 20 high-yield NICE conditions

These are the twenty conditions whose NICE stepwise management you must know verbatim for the AKT. They recur in question banks, they recur in past student reports, and they map cleanly onto the GMC content map's 212 presentations. Drill these before anything else.

1. Hypertension (NG136 / CKS) — the single most-tested prescribing pathway.
2. Type 2 diabetes (NG28) — metformin → SGLT2/GLP-1/sulfonylurea escalation.
3. Asthma (NG245 — the new 2024 BTS/NICE/SIGN joint guideline replacing NG80).
4. COPD (NG115) — MRT/LABA/LAMA combinations, pulmonary rehab thresholds.
5. Heart failure (NG106) — ACE inhibitor + beta-blocker + MRA quadruple therapy.
6. Atrial fibrillation (NG196) — CHA₂DS₂-VASc, HAS-BLED, DOAC first-line.
7. Depression in adults (NG222) — stepped care, SSRI first-line, duration rules.
8. Anxiety (GAD) (CG113) — CBT before medication, SSRI if meds indicated.
9. Chronic kidney disease (NG203) — ACEi + SGLT2, referral criteria.
10. Stroke/TIA (NG128) — aspirin 300 mg then clopidogrel, DOAC vs warfarin.
11. Acute coronary syndrome (NG185) — MONA-B, DAPT, secondary prevention.
12. Venous thromboembolism (NG158) — apixaban/rivaroxaban first-line.
13. UTI (CKS) — nitrofurantoin first-line for uncomplicated lower UTI.
14. Community-acquired pneumonia (CG191) — CURB-65, amoxicillin first-line.
15. Cellulitis (CKS) — flucloxacillin; clarithromycin if penicillin-allergic.
16. Migraine (CG150) — triptan + NSAID for acute, propranolol/topiramate for prevention.
17. Epilepsy (NG217) — sodium valproate contraindications, lamotrigine/levetiracetam.
18. Osteoporosis (NG254 / CKS) — FRAX, alendronate first-line, vitamin D/calcium.
19. Menopause (NG23) — HRT indications, risk-benefit counselling.
20. Contraception (FSRH guidelines, which NICE references) — UKMEC categories.

Make a single A4 page per condition. On that page: the stepwise ladder, the monitoring schedule, the "when to refer" triggers, and three worked examples of question stems. That's twenty pages of high-value revision that will cover perhaps 30–40% of every prescribing stem on the AKT.

4. NICE stepwise ladders explained

The phrase "stepwise ladder" is the key to NICE-based reasoning. Every chronic condition has a linear escalation — step 1, step 2, step 3 — where you climb the ladder only if the previous step fails to achieve target. Stems will give you a patient somewhere on the ladder and ask for the next step.

The hypertension ladder (NG136, 2019, still current in 2026) is the archetype and worth memorising exactly:

• Step 1: ACE inhibitor (ACEi) or ARB if age <55 and not of Black African/Caribbean origin. Calcium channel blocker (CCB) if age ≥55 or Black African/Caribbean origin. For patients with T2DM, ACEi/ARB regardless of age or ethnicity.
• Step 2: Add the other (so ACEi + CCB, or CCB + ACEi).
• Step 3: Add a thiazide-like diuretic (indapamide preferred over bendroflumethiazide).
• Step 4 (resistant hypertension): Add spironolactone if potassium ≤4.5; add alpha-blocker or beta-blocker if potassium >4.5.

Two features of this ladder trip up IMGs repeatedly. First, the age-55 and ethnicity cutoffs — they feel arbitrary but they reflect renin physiology and are heavily tested. Second, the T2DM override — a 45-year-old of Black African origin with T2DM gets an ACEi, not a CCB, because the diabetic renal-protection logic supersedes the ethnicity rule.

Stems will twist these cutoffs. A 56-year-old of White British origin? CCB first-line, because 55 is a ≥ threshold. A 54-year-old of Caribbean origin with T2DM? ACEi, because diabetes overrides. A 60-year-old of White British origin with CKD stage 3? ACEi, because CKD also overrides. Memorise the ladder, then memorise the overrides.

The T2DM ladder (NG28) follows the same logic: metformin step 1, then step 2 adds a second agent (SGLT2 inhibitor preferred in patients with established cardiovascular disease, heart failure, or CKD; GLP-1 agonist if BMI ≥35 with comorbidities; sulfonylurea or DPP-4 otherwise). Step 3 triple therapy, step 4 insulin.

Drill five or six ladders until you can write them out blind, then move to the next batch. Spaced-repetition flashcards work particularly well here — each ladder becomes a cloze-deletion card. The active recall and spaced repetition workflow is exactly the right scaffolding for NICE memorisation.

5. How UKMLA tests NICE knowledge

AKT prescribing stems follow five recurring templates. Recognising the template tells you what the question is actually testing and which part of the NICE guideline to retrieve.

Template 1 — First-line initiation. "A 56-year-old presents to GP with newly diagnosed X. Which is the most appropriate first-line agent?" This is a pure step-1 retrieval. Low-hanging marks if you know the ladder.

Template 2 — Escalation. "A 48-year-old is on drug Y for condition X. BP remains above target. What is the most appropriate next step?" This tests whether you know step 2.

Template 3 — Contraindication substitution. "A 65-year-old with asthma has newly diagnosed HTN." Step 1 would normally be ACEi, but the patient has asthma — which doesn't change anything for HTN. Or: "A 60-year-old with bilateral renal artery stenosis." Now ACEi is out, CCB or ARB with caution. This tests whether you know the cautions and contraindications box.

Template 4 — Monitoring. "A 58-year-old has just been started on ramipril. What monitoring is required?" This tests the prescribing-information section — U&Es in 1–2 weeks, then 2–4 weeks after any dose change.

Template 5 — Referral trigger. "At what eGFR should a patient with T2DM be referred to nephrology?" Or "which HbA1c level would prompt triple therapy?" These test the "when to refer" or "when to escalate" triggers buried at the end of each CKS management section.

Train yourself to tag each stem as one of these five templates as you read it. That tag tells you what to retrieve and prevents the common IMG mistake of over-thinking a straightforward retrieval question. These templates also appear in CPSA data-interpretation stations, so your CPSA preparation benefits directly from the same drilling.

6. UK vs US prescribing differences

If you trained in a US-curriculum medical school or absorbed your pharmacology from USMLE materials, this section alone may be worth 10–15 AKT marks.

Hypertension. US guidelines (JNC8, ACC/AHA 2017) are more permissive about thiazides and CCBs as first-line across age and ethnicity. UK practice per NICE uses the age-55 and ethnicity rules above. Pick the UK answer on the AKT.

Diabetes. US guidelines escalate to insulin much earlier and emphasise patient preference in step 2. UK NG28 is more prescriptive — SGLT2 inhibitor is the preferred step 2 add-on for most patients, not a GLP-1.

Asthma. The 2024 joint BTS/NICE/SIGN guideline (NG245) collapsed the previous stepladder into an anti-inflammatory-reliever-first approach (low-dose ICS/formoterol PRN as step 1, moving away from SABA monotherapy). This is a substantial change and is heavily examined on post-2024 papers. If your notes predate 2024, update them before exam day.

Antibiotics. UK stewardship is aggressively narrow-spectrum. Uncomplicated lower UTI gets nitrofurantoin, not ciprofloxacin. Simple community-acquired pneumonia gets amoxicillin, not ceftriaxone. Cellulitis gets flucloxacillin, not cephalexin. US stems sometimes normalise broader-spectrum agents. UK AKT stems will mark those wrong.

Anticoagulation. UK practice has shifted almost entirely to DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) for AF and VTE. Warfarin is now reserved for mechanical valves, antiphospholipid syndrome, and severe renal impairment. If a stem offers warfarin as an option for a standard AF patient, it is almost certainly the distractor.

Depression. UK NG222 uses stepped care with a stronger emphasis on CBT, behavioural activation, and psychological therapies before SSRIs for mild-to-moderate depression. US practice tends to start an SSRI earlier. On the AKT, if the stem describes mild depression in a 22-year-old with no risk features, the answer is likely a psychological intervention, not sertraline.

Spend one evening reading a single summary comparison of UK-vs-US prescribing for these six areas. That reading alone will measurably improve your AKT score if you trained abroad. It's the same reasoning the UKMLA for IMGs post highlights as the top preventable failure mode.

7. BNF structure and drug interactions

The British National Formulary is the other half of the UK prescribing universe. NICE tells you what to prescribe; the BNF tells you how. Both are tested.

Every BNF drug monograph has a fixed ten-section structure. The high-yield sections for AKT are:

• Indications and dose — the licensed indications and the standard doses. Dose ranges matter; specific numbers are sometimes tested.
• Cautions — conditions where the drug can be given but with careful monitoring.
• Contraindications — absolute bars. These are the distractors in "which drug is safe?" stems.
• Side-effects — especially the common, serious, and unique side-effects. "Dry cough on ACEi" and "gum hyperplasia on phenytoin" are classic stems.
• Interactions — the BNF's appendix 1 is the definitive UK reference. Learn the high-yield interactions listed below.

Drug interactions you must know cold for AKT:

• Warfarin + antibiotics (especially clarithromycin, metronidazole) — INR rises dangerously.
• Simvastatin + clarithromycin — increased myopathy/rhabdomyolysis risk.
• SSRI + MAOI — serotonin syndrome.
• SSRI + NSAID — GI bleed risk.
• Lithium + NSAID/ACEi/thiazide — lithium toxicity.
• Methotrexate + trimethoprim — bone marrow suppression.
• Statin + fibrate — rhabdomyolysis.
• Digoxin + diuretic (via hypokalaemia) — digoxin toxicity.
• Amiodarone + warfarin / digoxin / statin — multiple interactions; amiodarone inhibits CYP3A4.
• COCP + enzyme-inducer (rifampicin, some AEDs) — contraceptive failure.

The BNF also contains prescribing in palliative care, in pregnancy, in renal impairment, and in hepatic impairment — all of which appear on AKT. The pregnancy appendix in particular is worth skimming — teratogens like sodium valproate, warfarin, ACEi, and tetracyclines recur regularly.

Access to the digital BNF is free for anyone in the UK via NICE's website and the BNF app. You should have it open alongside every NICE page you read during revision. If you are outside the UK, the app still works — you may just need to register with a UK-based NHS email where one is available.

Treat BNF familiarity as non-negotiable. The single best way to improve is to start every prescribing flashcard by asking "what does the BNF say?" — the app search takes under 10 seconds and the answer is authoritative. If you want a structured framework to anchor this reading, the free diagnostic mock surfaces which prescribing categories you are weakest in within 20 minutes.

8. Drug naming pitfalls

UK drug names frequently differ from US and international names. The AKT uses UK generic names exclusively. If a stem asks about "albuterol" you will not see that option — you will see salbutamol. Know the mappings.

High-frequency name conflicts:

Common insulin names. UK practice uses generic names — Humulin M3, NovoMix 30, Lantus (glargine), Levemir (detemir), Tresiba (degludec), Humalog (lispro), NovoRapid (aspart). Stems will test rapid-acting vs long-acting vs biphasic. Know at least one example of each class.

Common antibiotic pitfalls. UK uses "co-amoxiclav" (amoxicillin-clavulanate). Co-trimoxazole (trimethoprim-sulfamethoxazole) is now rarely used in the UK except for PCP prophylaxis. Cephalosporins are avoided in primary care for stewardship reasons — if a stem's stem antibiotic is cefuroxime in a GP setting, suspect it's the distractor.

Bisphosphonate naming. Alendronic acid = alendronate. Both are correct in the UK; the active agent is the acid form in most formulations. The AKT will accept either on recognition but use "alendronic acid" in its own stems.

This is a one-evening fix. Build a flashcard deck with 40–60 name pairs and drill it twice. It disproportionately protects you on stems where the correct answer hinges on identifying a UK-named drug buried in a list of options.

9. Renal dosing essentials

Renal dose adjustment is a recurring AKT theme and an area where international candidates frequently drop marks. The BNF's appendix 3 ("prescribing in renal impairment") is the authoritative source; memorising its high-yield rules saves significant exam time.

Drugs that must be dose-reduced in CKD or eGFR <30:

• Direct oral anticoagulants (DOACs) — apixaban 2.5 mg BD if two of: age ≥80, weight ≤60 kg, creatinine ≥133. Rivaroxaban and edoxaban have their own CrCl thresholds.
• Enoxaparin (LMWH) — halve the prophylactic and treatment doses in CKD 4–5.
• Metformin — stop at eGFR <30; halve at eGFR 30–45.
• Gliclazide — caution at eGFR <45.
• SGLT2 inhibitors — initiation thresholds vary (dapagliflozin ≥15, empagliflozin ≥20 typically), but all continue below eGFR 30 in heart failure and CKD.
• Opioids — avoid morphine in renal failure; prefer oxycodone or fentanyl.
• Trimethoprim — halve dose below eGFR 30.
• Digoxin — reduce dose and monitor level.
• Lithium — toxicity risk; avoid if possible in CKD.
• Gentamicin — dose by nomogram/level; avoid if alternatives exist.

Drugs to avoid or use with extreme caution in CKD:

• NSAIDs — nephrotoxic; avoid.
• Spironolactone — hyperkalaemia risk in advanced CKD.
• Potassium-sparing diuretics.

Drugs that remain safe at most eGFRs: paracetamol, beta-blockers, CCBs, most antihypertensives, most SSRIs (with dose caution for citalopram at high doses), most statins.

Learn the eGFR thresholds (<60, <45, <30, <15) and which drugs flip at each. That's ten flashcards of enormous value.

10. Cost-efficacy reasoning (UK generic-first)

NICE bakes cost-effectiveness into every recommendation. This manifests on AKT stems as a preference for the cheapest equally-effective option. If two drugs are clinically equivalent, the UK answer is the one the NHS pays less for — which is almost always the generic.

Examples:

• Statins. Atorvastatin 20 mg is the UK first-line (cheap generic, plus CV-event reduction data from CARDS and ASCOT-LLA). Rosuvastatin is reserved for intolerance or specific high-risk patients. Simvastatin is older, has more interactions, and is largely superseded.
• PPIs. Omeprazole or lansoprazole (both generic, cheap) are preferred over esomeprazole or rabeprazole.
• SSRIs. Sertraline and citalopram are cost-preferred; fluoxetine and paroxetine are fine but less commonly initiated; escitalopram is a branded-cost issue and rarely first-line.
• Inhalers. UK guidelines now favour dry-powder inhalers over metered-dose for environmental reasons (carbon-footprint policy is in NICE guidance); this is occasionally tested.
• Beta-blockers. Bisoprolol for heart failure, atenolol only second-line (and declining), propranolol for migraine and anxiety.

If two options in a stem are clinically reasonable and one is obviously cheaper or more widely used in UK primary care, pick the cheaper/generic one. It is almost always the intended answer.

11. Extracting high-yield points from NICE pages

NICE CKS pages are long. A full read of a single CKS topic can consume 30–45 minutes, which is unsustainable across 50 topics. You need a 12-minute extraction protocol that gets you the AKT-relevant material without the rest.

The 12-minute protocol:

1. Minutes 0–2 — Summary. Read the top-of-page summary paragraph. This gives you the condition in one breath.
2. Minutes 2–4 — Scenarios. Scan the "Scenario" section headings under Management. These are the clinical contexts (e.g. "adult with newly diagnosed", "pregnant woman", "child over 5"). Each scenario has its own ladder.
3. Minutes 4–8 — Step 1/2/3. For each scenario, write down the step 1, step 2, step 3 drugs on a flashcard. Include doses if specified.
4. Minutes 8–10 — Monitoring. Read the prescribing information section for monitoring schedules and key cautions. Write a one-line monitoring rule per drug.
5. Minutes 10–12 — Referral/red flags. Note the "when to refer" triggers — eGFR thresholds, HbA1c thresholds, symptom red flags, pregnancy status.

You now have a one-side-of-A4 summary per condition in 12 minutes. Twenty topics = four hours. Do this across two evenings in weeks 4–6 of the 12-week UKMLA study plan and your NICE baseline is essentially complete.

What to skip: the background/epidemiology section, the "basis for recommendation" rationale section, the full reference list, and the detailed patient information leaflets. These are useful for clinical work but not for exam retrieval.

12. Exam technique: NICE-aligned answers

Three exam-room habits convert NICE knowledge into marks.

Habit 1 — Ask "what would a UK F1 do?" Before you pick an answer, consciously ask whether this option matches UK primary or secondary care. If three options are "medically reasonable" but only one is UK-standard, the UK-standard answer is almost always correct.

Habit 2 — Identify the scenario before the drug. Most AKT prescribing stems embed the scenario in the first sentence. Age, ethnicity, comorbidities, pregnancy, and renal function are the five pivots that determine which rung of the ladder the patient sits on. Identify those first, then retrieve the corresponding NICE step.

Habit 3 — Watch for contraindication overrides. If the stem includes a specific comorbidity (asthma, bilateral renal artery stenosis, pregnancy, severe CKD, potassium >5), that detail is almost certainly the discriminator. Ask yourself which option is contraindicated and eliminate it first.

Time discipline: a pure retrieval question should take 30–40 seconds. If you find yourself spending 90 seconds on a prescribing stem, you don't know the ladder — flag it, pick the best guess, and move on. Your pass mark target is built on answering knowable questions correctly, not on wrestling with unfamiliar ones.

Halfway point — if NICE coverage has been your weakest area on mock papers, our platform generates personalised prescribing-stem sets from the exact conditions you're scoring worst on, then re-tests you on a spaced-repetition schedule. Start your free diagnostic and get 20 AKT-style NICE stems tagged to your weakest conditions in under 30 minutes.

13. Free vs paid NICE resources

Free and essential:

• NICE CKS (cks.nice.org.uk) — the primary source. Free for everyone.
• NICE Guidelines (nice.org.uk/guidance) — free.
• BNF online and BNF app — free in the UK via NICE; app works internationally.
• BNFc (children) — free, relevant for paediatrics stems.
• Electronic Medicines Compendium (eMC) (medicines.org.uk) — full SPCs for every UK-licensed drug. Useful for deep-dive monograph questions.

Paid:

• Oxford Handbook of Clinical Specialties / Clinical Medicine / General Practice — not NICE-specific but good gap-filling reference.
• Pulse and GP Online — newsy summaries of guideline changes. Not essential.
• Q-bank NICE question sets — Passmedicine and Quesmed both tag questions by NICE guideline; useful for targeted practice (more on this in the question bank comparison).

Skip:

• UpToDate — excellent resource, but its guidance is US-biased. For UKMLA, trust NICE and the BNF only.
• WebMD / Medscape / AAFP — US-focused.
• International society guidelines (ESC, ACC/AHA, GINA) — useful for context but not authoritative for AKT.

The rule is: if it doesn't publish in .gov.uk, .nhs.uk, or nice.org.uk, treat it as background reading and not exam source.

14. Q-bank practice for NICE-based questions

Knowing NICE is not the same as answering NICE stems at speed. The second skill requires volume exposure. Both Passmedicine and Quesmed tag questions by originating guideline — use that tagging aggressively.

Workflow:

1. Pick one condition per day (e.g. Monday = HTN, Tuesday = T2DM).
2. Read the CKS page using the 12-minute protocol.
3. Do 20 Q-bank questions filtered to that guideline.
4. Review every wrong answer — for each, write the exact NICE step you missed.
5. At the end of the week, re-do any flagged questions.

Over 20 days you will have cycled through all 20 high-yield conditions with 400 targeted questions. Most candidates who do this systematically see a 15–20 percentage-point improvement on prescribing-stem subscores between first and third attempts.

If you are using spaced-repetition flashcards (Anki, RemNote, or similar — see the active recall guide), build cloze-deletion cards for each ladder step and each BNF caution. Flashcards outperform re-reading by a wide margin for this kind of discrete, fact-heavy material.

15. FAQ

How many AKT marks come from NICE knowledge? Approximately 30–50 of a 200-question paper involve a direct NICE-guideline reference. Another 20–30 test prescribing mechanics via the BNF. Together they are the single largest teachable content chunk on the paper.

Do I need to memorise NICE guideline numbers (NG185, NG28)? No. The AKT will never ask "which NG number covers asthma?" You need to know the content, not the catalogue entry.

The 2024 asthma guideline changed everything — do I need to restudy? If your primary revision happened before August 2024, yes — the anti-inflammatory-reliever-first approach is genuinely new and is being tested. NG245 replaced NG80 and reframes step 1.

How often does NICE update guidelines? Major guidelines are reviewed every 3–5 years; CKS topics are updated more frequently (often annually for high-traffic conditions). Check the "last updated" date on each CKS page. For AKT in 2026, any guideline dated 2024 or later is likely to be tested aggressively because it reflects recent changes.

What if two NICE guidelines seem to conflict? They rarely do. If they appear to, the more recent and more specific one wins. For example, heart failure patients with T2DM: the HF guideline (NG106) and the T2DM guideline (NG28) both apply, but both point to the same answer (SGLT2 inhibitor with cardiovascular-outcome benefit).

Do IMGs really need to restudy pharmacology from scratch? No — the underlying physiology and drug classes are universal. What you need to restudy is UK-specific first-line choice, UK generic naming, and UK stepwise ladders. That is a 40-hour task, not a 400-hour one, if you execute the 12-minute CKS protocol systematically.

How is NICE knowledge tested on CPSA? It's tested implicitly rather than explicitly. A CPSA station will ask you to "counsel the patient on their new antihypertensive" — you need to know the monitoring (U&Es in 1–2 weeks for ACEi), the common side-effects (dry cough, angio-oedema), and the safety netting (come back if swelling, pregnancy plans). That comes directly from the NICE/BNF prescribing information section. The CPSA strategy post covers how to weave this into station prep.

What if I still feel unprepared two weeks before AKT? Focus exclusively on the top 20 conditions in section 3 of this post. Drop everything else. Twenty conditions, twenty ladders, twenty flashcard sets. Most AKT underperformance on prescribing stems is not caused by obscure conditions — it's caused by shaky grasp of the common ones.

---

NICE isn't optional and it isn't hard. It's finite, it's free, it's online, and the AKT rewards you disproportionately for knowing it cold. If you budget one evening per week for twelve weeks on the top 20 conditions and the BNF drug-interaction list, you will walk into the AKT confident on 40–50 prescribing stems that many IMGs and even some UK students fumble.

The IMG knowledge gap is real but it's closeable in under 40 hours of focused work. Start with hypertension tonight. Write the ladder from memory tomorrow. Do 20 Passmedicine questions on it by Friday. Then move to T2DM. By the time you reach condition 20, the pattern-recognition is automatic and your AKT prescribing subscore has already moved.

MLA Prep tags every practice question by NICE guideline and rebuilds your question set weekly based on your weakest ladders — the same 12-week drilling workflow described above, automated. Compare our plans or sign up for the free diagnostic and see which of the top 20 conditions you need to prioritise first.